In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named "2019 novel coronavirus(2019-nCoV)" by the World Health Organization(WHO) on 12 January 2020. For it is a n...In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named "2019 novel coronavirus(2019-nCoV)" by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.展开更多
In December 2019,several patients with pneumonia of an unknown cause were detected in Wuhan,China.On 7 January 2020,the causal organism was identified as a new coronavirus,later named as the 2019 novel coronavirus(201...In December 2019,several patients with pneumonia of an unknown cause were detected in Wuhan,China.On 7 January 2020,the causal organism was identified as a new coronavirus,later named as the 2019 novel coronavirus(2019-nCoV).Genome sequencing found the genetic sequence of 2019-nCoV homologous to that of severe acute respiratory syndrome-associated coronavirus.As of 29 January 2020,the virus had been diagnosed in more than 7000 patients in China and 77 patients in other countries.It is reported that both symptomatic and asymptomatic patients with 2019-nCoV can play a role in disease transmission via airborne and contact.This finding has caused a great concern about the prevention of illness spread.The clinical features of the infection are not specific and are often indistinguishable from those of other respiratory infections,making it difficult to diagnose.Given that the virus has a strong ability to spread between individuals,it is of top priority to identify potential or suspected patients as soon as possible—or the virus may cause a serious pandemic.Therefore,a precision medicine approach to managing this disease is urgently needed for detecting and controlling the spread of the virus.In this article,we present such an approach to managing 2019-nCoV-related pneumonia based on the unique traits of the virus recently revealed and on our experience with coronaviruses at West China Hospital in Chengdu,China.展开更多
Objective: In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral respiratory infections and also contain compounds that might directly inhibit 2019 novel...Objective: In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral respiratory infections and also contain compounds that might directly inhibit 2019 novel coronavirus(2019-nCoV), an ongoing novel coronavirus that causes pneumonia.Methods: There were two main steps in the screening process. In the first step we conducted a literature search for natural compounds that had been biologically confirmed as against sever acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus. Resulting compounds were cross-checked for listing in the Traditional Chinese Medicine Systems Pharmacology Database.Compounds meeting both requirements were subjected to absorption, distribution, metabolism and excretion(ADME) evaluation to verify that oral administration would be effective. Next, a docking analysis was used to test whether the compound had the potential for direct 2019-nCoV protein interaction.In the second step we searched Chinese herbal databases to identify plants containing the selected compounds. Plants containing 2 or more of the compounds identified in our screen were then checked against the catalogue for classic herbal usage. Finally, network pharmacology analysis was used to predict the general in vivo effects of each selected herb.Results: Of the natural compounds screened, 13 that exist in traditional Chinese medicines were also found to have potential anti-2019-nCoV activity. Further, 125 Chinese herbs were found to contain 2 or more of these 13 compounds. Of these 125 herbs, 26 are classically catalogued as treating viral respiratory infections. Network pharmacology analysis predicted that the general in vivo roles of these26 herbal plants were related to regulating viral infection, immune/inflammation reactions and hypoxia response.Conclusion: Chinese herbal treatments classically used for treating viral respiratory infection might contain direct anti-2019-nCoV compounds.展开更多
Based on the announcement of the World Health Organization(WHO) in 2018, the Wuhan pneumonia caused by an unknown etiology should be recognized as the first Disease X. Later, the pathogen was identified to be a novel ...Based on the announcement of the World Health Organization(WHO) in 2018, the Wuhan pneumonia caused by an unknown etiology should be recognized as the first Disease X. Later, the pathogen was identified to be a novel coronavirus denoted 2019-nCoV, which has 79.5% and 96% whole genome sequence identify to SARS-CoV and bat SARS-related coronavirus(SARSr-CoV-RaTG13), respectively, suggesting its potential bat origin. With high human-to-human transmission rate(R0), 2019-nCoV has quickly spread in China and other countries, resulting in 34,953 confirmed cases and 725 deaths as of 8 February 2020, thus calling for urgent development of therapeutics and prophylactics. Here we suggest renaming 2019-nCoV as "transmissible acute respiratory syndrome coronavirus(TARS-CoV)" and briefly review the advancement of research and development of neutralizing antibodies and vaccines targeting the receptor-binding domain(RBD) and viral fusion inhibitors targeting the heptad repeat 1(HR1) domain in spike protein of 2019-nCoV.展开更多
Since the outbreak of coronavirus disease 2019(COVID-19),the author has been involved in the treatment of COVID-19 in the first line.It is found that some patients had a long viral nucleic acid negative time,and even ...Since the outbreak of coronavirus disease 2019(COVID-19),the author has been involved in the treatment of COVID-19 in the first line.It is found that some patients had a long viral nucleic acid negative time,and even the course of the disease lasted more than 40 days.After a thorough investigation of the root causes,it is found the four possible causes were:"Blood stasis syndrome"is difficult to remove;"Damp heat"sticky greasy;Stubborn basic diseases;weak constitution.All the patients treated with traditional Chinese medicine have turned negative,and now the typical cases were analyzed and summarized in order to provide reference for the traditional Chinese medicine treatment and scientific research of the patients with COVID-19 who were difficult to turn negative.展开更多
The COVID-19 caused by a novel strain of coronavirus has been spreading rapidly since its occurrence in December 2019.It is highly communicable through human-to-human transmission.China has been making unprecedented e...The COVID-19 caused by a novel strain of coronavirus has been spreading rapidly since its occurrence in December 2019.It is highly communicable through human-to-human transmission.China has been making unprecedented efforts in treating the confirmed cases,identifying and isolating their close contacts and suspected cases to control the source of infection and cut the route of transmission.China’s devotion in handling this epidemic has effectively and efficiently curbed communication domestically and across the border.Representative measures adopted by Wenzhou,the worst hit city out of Hubei Province,are examined to elucidate those massive undertakings with the aim of enhancing international understanding and building global rapport in fighting this evolving epidemic situation.展开更多
基金supported(in part)by the Entrusted Project of National Center for Medical Service Administration,National Health and Family Planning Commission China(No.[2019]099)the First Level Funding of the Second Medical Leading Talent Project in Hubei Provincethe Special Project for Emergency of the Ministry of Science and Technology(2020YFC0841300)。
文摘In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named "2019 novel coronavirus(2019-nCoV)" by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.
基金This article was supported by the National Key Development Plan for Precision Medicine Research(2017YFC0910004).
文摘In December 2019,several patients with pneumonia of an unknown cause were detected in Wuhan,China.On 7 January 2020,the causal organism was identified as a new coronavirus,later named as the 2019 novel coronavirus(2019-nCoV).Genome sequencing found the genetic sequence of 2019-nCoV homologous to that of severe acute respiratory syndrome-associated coronavirus.As of 29 January 2020,the virus had been diagnosed in more than 7000 patients in China and 77 patients in other countries.It is reported that both symptomatic and asymptomatic patients with 2019-nCoV can play a role in disease transmission via airborne and contact.This finding has caused a great concern about the prevention of illness spread.The clinical features of the infection are not specific and are often indistinguishable from those of other respiratory infections,making it difficult to diagnose.Given that the virus has a strong ability to spread between individuals,it is of top priority to identify potential or suspected patients as soon as possible—or the virus may cause a serious pandemic.Therefore,a precision medicine approach to managing this disease is urgently needed for detecting and controlling the spread of the virus.In this article,we present such an approach to managing 2019-nCoV-related pneumonia based on the unique traits of the virus recently revealed and on our experience with coronaviruses at West China Hospital in Chengdu,China.
基金supported by Shanghai Leading Talent Grants in Medicine(No.2019LG26)Shanghai Traditional Chinese Medicine Content Construction Innovation Project(No.ZY3-CCCX-3-7001)Postdoctoral Funding of Shanghai Gongil Hospital(No.GLBH2017002).
文摘Objective: In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral respiratory infections and also contain compounds that might directly inhibit 2019 novel coronavirus(2019-nCoV), an ongoing novel coronavirus that causes pneumonia.Methods: There were two main steps in the screening process. In the first step we conducted a literature search for natural compounds that had been biologically confirmed as against sever acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus. Resulting compounds were cross-checked for listing in the Traditional Chinese Medicine Systems Pharmacology Database.Compounds meeting both requirements were subjected to absorption, distribution, metabolism and excretion(ADME) evaluation to verify that oral administration would be effective. Next, a docking analysis was used to test whether the compound had the potential for direct 2019-nCoV protein interaction.In the second step we searched Chinese herbal databases to identify plants containing the selected compounds. Plants containing 2 or more of the compounds identified in our screen were then checked against the catalogue for classic herbal usage. Finally, network pharmacology analysis was used to predict the general in vivo effects of each selected herb.Results: Of the natural compounds screened, 13 that exist in traditional Chinese medicines were also found to have potential anti-2019-nCoV activity. Further, 125 Chinese herbs were found to contain 2 or more of these 13 compounds. Of these 125 herbs, 26 are classically catalogued as treating viral respiratory infections. Network pharmacology analysis predicted that the general in vivo roles of these26 herbal plants were related to regulating viral infection, immune/inflammation reactions and hypoxia response.Conclusion: Chinese herbal treatments classically used for treating viral respiratory infection might contain direct anti-2019-nCoV compounds.
文摘Based on the announcement of the World Health Organization(WHO) in 2018, the Wuhan pneumonia caused by an unknown etiology should be recognized as the first Disease X. Later, the pathogen was identified to be a novel coronavirus denoted 2019-nCoV, which has 79.5% and 96% whole genome sequence identify to SARS-CoV and bat SARS-related coronavirus(SARSr-CoV-RaTG13), respectively, suggesting its potential bat origin. With high human-to-human transmission rate(R0), 2019-nCoV has quickly spread in China and other countries, resulting in 34,953 confirmed cases and 725 deaths as of 8 February 2020, thus calling for urgent development of therapeutics and prophylactics. Here we suggest renaming 2019-nCoV as "transmissible acute respiratory syndrome coronavirus(TARS-CoV)" and briefly review the advancement of research and development of neutralizing antibodies and vaccines targeting the receptor-binding domain(RBD) and viral fusion inhibitors targeting the heptad repeat 1(HR1) domain in spike protein of 2019-nCoV.
基金Science and Technology Research Project of Jiangxi Provincial Department of Science and Technology(No.S2020ZPYFG0006)Training Project of National Traditional Chinese Medicine Innovative Key Talents National Chinese Medicine(2019)(No.128)
文摘Since the outbreak of coronavirus disease 2019(COVID-19),the author has been involved in the treatment of COVID-19 in the first line.It is found that some patients had a long viral nucleic acid negative time,and even the course of the disease lasted more than 40 days.After a thorough investigation of the root causes,it is found the four possible causes were:"Blood stasis syndrome"is difficult to remove;"Damp heat"sticky greasy;Stubborn basic diseases;weak constitution.All the patients treated with traditional Chinese medicine have turned negative,and now the typical cases were analyzed and summarized in order to provide reference for the traditional Chinese medicine treatment and scientific research of the patients with COVID-19 who were difficult to turn negative.
文摘The COVID-19 caused by a novel strain of coronavirus has been spreading rapidly since its occurrence in December 2019.It is highly communicable through human-to-human transmission.China has been making unprecedented efforts in treating the confirmed cases,identifying and isolating their close contacts and suspected cases to control the source of infection and cut the route of transmission.China’s devotion in handling this epidemic has effectively and efficiently curbed communication domestically and across the border.Representative measures adopted by Wenzhou,the worst hit city out of Hubei Province,are examined to elucidate those massive undertakings with the aim of enhancing international understanding and building global rapport in fighting this evolving epidemic situation.
